Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open‐Label Extension of a Randomized Clinical Trial

OBJECTIVE: This post hoc analysis evaluated the safety and efficacy of open‐label sarilumab in patients with rheumatoid arthritis (RA) who completed the phase III double‐blind ASCERTAIN study (NCT01768572) and switched from intravenous (IV) tocilizumab to subcutaneous (SC) sarilumab, or who continue...

Descripción completa

Detalles Bibliográficos
Autores principales: Emery, Paul, van Hoogstraten, Hubert, Thangavelu, Karthinathan, Mangan, Erin, St John, Gregory, Verschueren, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672306/
https://www.ncbi.nlm.nih.gov/pubmed/33164349
http://dx.doi.org/10.1002/acr2.11188

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672306/
https://www.ncbi.nlm.nih.gov/pubmed/33164349
http://dx.doi.org/10.1002/acr2.11188

Ejemplares similares